Literature DB >> 23155237

Cytotoxicity and type of cell death induced by midazolam in human oral normal and tumor cells.

Seika Ohno1, Katsue Kobayashi, Shigenori Uchida, Osamu Amano, Hiroshi Sakagami, Hiroshi Nagasaka.   

Abstract

BACKGROUND: Intravenous anesthetics have been used during the treatment of various malignant tumors, however, their effects on oral tissues is not well-understood. In the present study, the cytotoxicity of five intravenous anesthetics towards oral tumor and normal cells was compared.
MATERIALS AND METHODS: Tumor specificity index was determined by the ratio of the mean 50% cytotoxic concentration for normal cells to that for tumor cells. Apoptosis induction was monitored by internucleosomal DNA fragmentation and caspase-3, -8, and -9 activation. Fine cell structure was observed under transmission electron microscopy.
RESULTS: Benzodiazepines (midazolam and diazepam) exhibited higher cytotoxicity than barbiturates (thiopental and thiamylal), whereas propofol had the intermediate range of cytotoxicity. Midazolam showed the highest cytotoxicity. HL-60 cells were the most sensitive to midazolam, followed by epidermal keratinocytes, oral squamous cell carcinoma (OSCC), glioblastoma and then oral normal cells. Midazolam did not induce the production of apoptosis markers such as internucleosomal DNA fragmentation and activation of caspase-3, -8 and -9, but did induce the appearance of many vacuoles, mitochondrial swelling and cell membrane rupture in OSCC cell lines (HSC-2 and HSC-4) cells. The cytotoxicity of midazolam was not reduced by pre-treatment with autophagy inhibitors (3-methyladenine and bafilomycin A1).
CONCLUSION: These results suggest that midazolam may induce necrotic cell death, rather than apoptosis or autophagy, in OSCC cell lines.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23155237

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  5 in total

1.  Midazolam induces A549 cell apoptosis in vitro via the miR-520d-5p/STAT3 pathway.

Authors:  Jinghua Jiao; Yuheng Wang; Xiaofeng Sun; Xiaojing Jiang
Journal:  Int J Clin Exp Pathol       Date:  2018-03-01

2.  Pretreatment but not subsequent coincubation with midazolam reduces the cytotoxicity of temozolomide in neuroblastoma cells.

Authors:  Sebastian Braun; Inge Bauer; Benedikt Pannen; Robert Werdehausen
Journal:  BMC Anesthesiol       Date:  2015-10-17       Impact factor: 2.217

Review 3.  Insights into the Roles of Midazolam in Cancer Therapy.

Authors:  Jinghua Jiao; Yuheng Wang; Xiaofeng Sun; Xiaojing Jiang
Journal:  Evid Based Complement Alternat Med       Date:  2017-06-19       Impact factor: 2.629

4.  Potential for Drug Repositioning of Midazolam for Dentin Regeneration.

Authors:  Takeo Karakida; Kazuo Onuma; Mari M Saito; Ryuji Yamamoto; Toshie Chiba; Risako Chiba; Yukihiko Hidaka; Keiko Fujii-Abe; Hiroshi Kawahara; Yasuo Yamakoshi
Journal:  Int J Mol Sci       Date:  2019-02-04       Impact factor: 5.923

5.  Anticancer Effects of Midazolam on Lung and Breast Cancers by Inhibiting Cell Proliferation and Epithelial-Mesenchymal Transition.

Authors:  Hsin-Ling Lu; King-Chuen Wu; Char-Wen Chen; Hong-Kai Weng; Bu-Miin Huang; Ting-Yu Lin; Ming-Hsin Liu; Edmund-Cheung So; Ruey-Mo Lin; Yang-Kao Wang
Journal:  Life (Basel)       Date:  2021-12-13
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.